Kimberly Wideman, MS

Project Manager, Epidemiology
RTI Health Solutions

Poster(s):

• ((A-333)) (A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((A-350)) (A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET